| Pharmaceutical Information |
| Drug Name |
Daunorubicin |
| Drug ID |
BADD_D00590 |
| Description |
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. |
| Indications and Usage |
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
Daunorubicin is indicated in combination with [cytarabine] for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.[L32843] |
| Marketing Status |
approved |
| ATC Code |
L01DB02 |
| DrugBank ID |
DB00694
|
| KEGG ID |
D07776
|
| MeSH ID |
D003630
|
| PubChem ID |
30323
|
| TTD Drug ID |
D01XWG
|
| NDC Product Code |
Not Available |
| UNII |
ZS7284E0ZP
|
| Synonyms |
Daunorubicin | Daunomycin | Rubomycin | Dauno-Rubidomycine | Dauno Rubidomycine | Rubidomycin | Daunoblastin | Daunoblastine | NSC-82151 | NSC 82151 | NSC82151 | Cerubidine | Daunorubicin Hydrochloride | Hydrochloride, Daunorubicin |
|
| Chemical Information |
| Molecular Formula |
C27H29NO10 |
| CAS Registry Number |
20830-81-3 |
| SMILES |
CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
